» Articles » PMID: 37046117

Hypotensive Effects of Arginase Inhibition by L-Norvaline in Genetic Models of Normotensive and Hypertensive Rats

Overview
Publisher Springer
Specialty General Medicine
Date 2023 Apr 12
PMID 37046117
Authors
Affiliations
Soon will be listed here.
Abstract

The main effect of arginase inhibition after administration of L-norvaline is a decrease in BP. At the same time, norvaline causes various side effects in normotensive and hypertensive animals. In our experiments, L-norvaline was administered intraperitoneally (30 mg/kg) for 7 days to normotensive WAG rats (Wistar Albino Glaxo) and hypertensive ISIAH rats (Inherited, Stress-Induced Arterial Hypertension). In ISIAH rats, BP decrease was accompanied by an increase in diuresis, while in WAG rats, diuresis remained unchanged or little changed. At the same time, hypertensive rats demonstrated an increase of catecholamine content in the adrenal glands, while in normotensive animals, it was decreased. The differences in the effects of norvaline can be associated with different mechanisms of BP maintenance in normotensive and hypertensive animals. Normally, BP is maintained by the regulatory influences of the nitric oxide system. In hypertension, this system is weakened, and the hypotensive effects are probably achieved via increased diuresis.

Citing Articles

Animal Models of Hypertension (ISIAH Rats), Catatonia (GC Rats), and Audiogenic Epilepsy (PM Rats) Developed by Breeding.

Ryazanova M, Plekanchuk V, Prokudina O, Makovka Y, Alekhina T, Redina O Biomedicines. 2023; 11(7).

PMID: 37509453 PMC: 10376947. DOI: 10.3390/biomedicines11071814.

References
1.
Pernow J, Jung C . The Emerging Role of Arginase in Endothelial Dysfunction in Diabetes. Curr Vasc Pharmacol. 2015; 14(2):155-62. DOI: 10.2174/1570161114666151202205617. View

2.
Shemyakin A, Kovamees O, Rafnsson A, Bohm F, Svenarud P, Settergren M . Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes mellitus. Circulation. 2012; 126(25):2943-50. DOI: 10.1161/CIRCULATIONAHA.112.140335. View

3.
Johnson F, Peyton K, Liu X, Azam M, Shebib A, Johnson R . Arginase promotes endothelial dysfunction and hypertension in obese rats. Obesity (Silver Spring). 2015; 23(2):383-90. PMC: 4310823. DOI: 10.1002/oby.20969. View

4.
Lucas R, Fulton D, Caldwell R, Romero M . Arginase in the vascular endothelium: friend or foe?. Front Immunol. 2014; 5:589. PMC: 4233309. DOI: 10.3389/fimmu.2014.00589. View

5.
Yang Z, Ming X . Endothelial arginase: a new target in atherosclerosis. Curr Hypertens Rep. 2006; 8(1):54-9. DOI: 10.1007/s11906-006-0041-8. View